Surgical management of prostate cancer metastatic to the spine

被引:48
|
作者
Williams, Brian J. [1 ]
Fox, Benjamin D. [1 ]
Sciubba, Daniel M. [4 ]
Suki, Dima [1 ]
Tu, Shi Ming [2 ]
Kuban, Deborah [3 ]
Gokaslan, Ziya L. [4 ]
Rhines, Laurence D. [1 ]
Rao, Ganesh [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[4] Johns Hopkins Univ Hosp, Dept Neurol Surg, Baltimore, MD 21287 USA
关键词
prostate cancer; metastasis; spinal surgery; outcome analysis; prognosis; QUALITY-OF-LIFE; CORD COMPRESSION; RADICAL PROSTATECTOMY; NATURAL-HISTORY; DISEASE; ANTERIOR; TUMORS; RESECTION; INSTRUMENTATION; STABILIZATION;
D O I
10.3171/2009.1.SPINE08509
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Object. Significant improvements in neurological function and pain relief are the benefits of aggressive surgical management of spinal metastatic disease. However, there is limited literature regarding the management of tumors with specific histological features. In this study, a series of patients undergoing spinal surgery for metastatic prostate cancer were reviewed to identify predictors of survival and functional outcome. Methods. The authors retrospectively reviewed the records of all patients who were treated with surgery for prostate cancer metastases to the spine between 1993 and 2005 at a single institution. Particular attention was given to initial presentation, operative management, clinical and neurological outcomes, and factors associated with complications and overall survival. Results. Forty-four patients underwent a total of 47 procedures. The median age at spinal metastasis was 66 years (range 50-84 years). Twenty-four patients had received previous external-beam radiation to the site of spinal involvement, with a median dose of 70 Gy (range 30-74 Gy). Frankel scores on discharge were significantly improved when compared with preoperative scores (p = 0.001). Preoperatively, 32 patients (73%) were walking and 33 (75%) were continent. On discharge, 36 (86%) of 42 patients were walking, and 37 (88%) of 42 were continent. Preoperatively, 40 patients (91%) were taking narcotics, with a median morphine equivalent dose of 21.5 mg/day, and 28 patients (64%) were taking steroids, with a median dose of 16 mg/day. At discharge, the median postoperative morphine equivalent dose was 12 mg/day, and the median steroid dose was 0 mg/day (p < 0.001). Complications occurred in 15 (32%) of 47 procedures, with 9 (19%) considered major, and there were 4 deaths within 30 days of surgery. The median overall survival was 5.4 months. Gleason score (p = 0.002), total number of metastases (p = 0.001), and the degree of spinal canal compression (p = 0.001) were independent predictors of survival. Age 2-65 years at the time of surgery was an independent predictor of a postoperative complication (p = 0.005). Conclusions. In selected patients with prostate cancer metastases to the spine, aggressive surgical decompression and spinal reconstruction is a useful treatment option. The results show that on average, neurological outcome is improved and use of analgesics is reduced. Gleason score, metastatic burden, and degree of spinal canal compression may be associated with survival following surgery, and thus should be considered carefully prior to opting for surgical management. (DOI: 10.3171/2009.1.SPINE08509)
引用
收藏
页码:414 / 422
页数:9
相关论文
共 50 条
  • [21] Surgical treatment for metastatic tumors of the spine
    Kawai, A
    Harada, Y
    Senda, M
    Sugihara, S
    Inoue, H
    Nakahara, S
    ACTA MEDICA OKAYAMA, 1996, 50 (01) : 29 - 35
  • [22] The metastatic cascade in prostate cancer
    Arya, Manit
    Bott, Simon R.
    Shergill, Iqbal S.
    Ahmed, Flashim U.
    Williamson, Magali
    Patel, Fliten R.
    SURGICAL ONCOLOGY-OXFORD, 2006, 15 (03): : 117 - 128
  • [23] Surgical management of prostate cancer
    Long, J. -A.
    Thuillier, C.
    Terrier, N.
    Descotes, J. -L.
    Rambeaud, J. -J.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2011, 35 (06): : 384 - 389
  • [24] The Surgical Management of Prostate Cancer
    Sebesta, Elisabeth M.
    Anderson, Christopher B.
    SEMINARS IN ONCOLOGY, 2017, 44 (05) : 347 - 357
  • [25] The prognostic significance of Gleason scores in metastatic prostate cancer
    Rusthoven, Chad G.
    Carlson, Julie A.
    Waxweiler, Timothy V.
    Yeh, Norman
    Raben, David
    Flaig, Thomas W.
    Kavanagh, Brian D.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (05) : 707 - 713
  • [26] Rationale for local treatment in the management of metastatic prostate cancer
    Gandaglia, Giorgio
    Fossati, Nicola
    Dell'Oglio, Paolo
    Moschini, Marco
    Cucchiara, Vito
    Suardi, Nazareno
    Mottrie, Alexandre
    Mirone, Vincenzo
    Montorsi, Francesco
    Briganti, Alberto
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2016, 10 (03) : 266 - 272
  • [27] Prolonged survival following aggressive treatment for metastatic breast cancer in the spine
    Zadnik, Patricia L.
    Hwang, Lee
    Ju, Derek G.
    Groves, Mari L.
    Sui, Jackson
    Yurter, Alp
    Witham, Timothy F.
    Bydon, Ali
    Wolinsky, Jean-Paul
    Gokaslan, Ziya L.
    Sciubba, Daniel M.
    CLINICAL & EXPERIMENTAL METASTASIS, 2014, 31 (01) : 47 - 55
  • [28] French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance
    Ploussard, Guillaume
    Dariane, Charles
    Mathieu, Romain
    Baboudjian, Michael
    Barret, Eric
    Brureau, Laurent
    Fiard, Gaelle
    Fromont, Gaelle
    Olivier, Jonathan
    Rozet, Francois
    Peyrottes, Arthur
    Renard-Penna, Raphaele
    Sargos, Paul
    Supiot, Stephane
    Turpin, Lea
    Roubaud, Guilhem
    Roupret, Morgan
    FRENCH JOURNAL OF UROLOGY, 2024, 34 (12):
  • [29] Medical management of metastatic prostate cancer
    Body, Amy
    Pranavan, Ganes
    Tan, Thean Hsiang
    Slobodian, Peter
    AUSTRALIAN PRESCRIBER, 2018, 41 (05) : 154 - 159
  • [30] Bisphosphonates in the management of metastatic prostate cancer
    Heidenreich, A
    ONCOLOGY, 2003, 65 : 5 - 11